Weight-loss drugs do work – but not on their own | Letters

Key data: an anecdotal patient reports losing a stone (~6.35 kg) in 3 months on Mounjaro at a personal cost of ~£600, with baseline BMI 28.5. The letters argue GLP‑1 medicines are an important therapeutic advance and may affect brain reward systems, but stress drugs alone rarely solve obesity — best outcomes combine pharmacology with diet, exercise, sleep and muscle preservation. Authors warn against polarized debate and call for broader public-health measures and possible legislative controls on the food environment and improved access to addiction treatments.

Analysis

The market is beginning to price GLP-1s as purely a drug-revenue story, but the highest-margin and stickiest economics will come from integrated care — subscription coaching, rehab/physiotherapy to preserve muscle, and telemedicine follow-up. That implies a rotation from one-time prescribers and spot sales into recurring-revenue service providers and CDMOs that can monetize long patient lifecycles; expect ARPU expansion per treated patient once service bundles are widely reimbursed.

Second-order winners are therefore not just the molecule creators but the logistics and services that enable durable outcomes: CDMOs and specialty clinics will see capex and contract upside as manufacturers scale injectables, while digital coaching platforms and telehealth operators can capture lifetime value via retention. Conversely, consumer-packaged-goods companies whose margins rely on impulse ultra-processed products face both demand erosion and regulatory risk over the 12–36 month horizon if advertising and packaging rules tighten.

Key risks that could reverse the theme are political/regulatory intervention on pricing and advertising, a persistent supply-side bottleneck that slows adoption, or a behavioral ceiling in real-world persistence that limits market penetration. Watch near-term catalysts: formulary decisions and large-payer pilot outcomes in the next 6–12 months, and legislative moves on food advertising or subsidy programs in the 12–36 month window; a safety signal or aggressive price-cap could compress multiples quickly.

Key Decisions for Investors

• Long LLY (Eli Lilly) via a 12–18 month call-spread to express tirzepatide adoption and label expansion. Rationale: molecule leader with near-term share gains; target 30–60% upside in a high-penetration scenario; use a debit call spread to cap premium risk (~100% of premium). Key risk: formulary/pricing intervention that can truncate upside.
• Long CTLT (Catalent) 6–12 months to capture CDMO/fill-finish tailwinds from injectable GLP-1 scale-up. Rationale: direct beneficiary of increased biologics manufacturing; target 20–35% upside as utilization lifts; risk: lumpy capex and multi-quarter lead times that can compress margins if demand misses.
• Pair trade (6–12 months): Long WW (WW International) + Long TDOC (Teladoc) to express subscription/behavioural capture; Short MDLZ (Mondelez) to tactically express regulatory/consumer-shift risk in ultra-processed snacks. Rationale: behavioral platforms monetize retention and coaching, while snack producers face incremental regulatory and demand risks. Risk/reward: asymmetric — limited downside in subscriptions if patient persistence proves sticky; downside concentrated if consumer demand remains resilient.
• Portfolio hedge: Buy 9–12 month OTM puts on NVO (Novo Nordisk) or a biotech ETF sized to cover 20–30% of GLP-1 exposure. Rationale: protects against abrupt regulatory pricing caps, adverse safety news, or rapid persistence roll-off. Cost is insurance premium versus catastrophic drawdown protection.